Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Synergen Inc. sales and marketing update

SYGN reported a loss of $18.2 million (72 cents per share)

Read the full 111 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE